Therefore, B16-OVA tumour-bearing mice were treated with 5 × 105 of each day-10 or day-20 in vitro expanded CD4+ Th1 cells and/or CD8+ CTLs (Figure 1a). This evidence concerns the gene CD8A and neoplasm.